EMEA-001194-PIP01-11-M05
Key facts
Invented name |
Galafold
|
Active substance |
Migalastat hydrochloride
|
Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
Decision number |
P/0126/2022
|
PIP number |
EMEA-001194-PIP01-11-M05
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of Fabry disease
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Amicus Therapeutics Europe Limited
E-mail: IR@amicusrx.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|